KPTI News and Press, Karyopharm Therapeutics Inc. From 11/01/18

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...

-- Conference Call Scheduled for Thursday, November 8, 2018 at 8:30 a.m. ET --  NEWTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2018 financi...

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. Genmab ( GNMSF ) and their par...

Karyopharm Therapeutics (NASDAQ: KPTI ) has issued an additional $22.5M aggregate principal amount of 3.00% convertible senior notes due 2025 pursuant to the exercise in full of the option to purchase additional notes granted to the initial purchasers in previously announced private offeri...

NEWTON, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that it has issued an additional $22.5 million aggregate principal amount of its 3.00% convertible senior notes due 2025 (the “notes&#...